List of Tables
Novartis AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20
Novartis AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21
Novartis AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22
Novartis AG, Deals By Therapy Area, 2012 to YTD 2018 23
Novartis AG, Medical Devices Deals, 2012 to YTD 2018 25
Novartis AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 27
Novartis Acquires Rare Pediatric Disease Priority Review Voucher from Ultragenyx Pharma for USD130 Million 62
Fougera Pharma Acquires US Rights to Veregen from Medigene 63
Novartis Institutes for BioMedical Research to Acquire Dynamic Tumor Targeting Platform Technology from Cerulean Pharma 64
Sandoz Acquires Product Portfolio of Euro-Pharm International Canada 66
Novartis Acquires Rights to Interleukin-17 from Ensemble Therapeutics 67
Novartis Acquires Rights of PF-06438179 from Pfizer 68
Sandoz Acquires Rights of Biosimilar Infliximab from Pfizer 69
Novartis Pharma Acquires Rights to Ofatumumab for Auto-Immune Indications from GlaxoSmithKline for up to USD1 Billion 70
Teva Pharma May Divest its Assets 71
Novartis Acquires Cancer Drugs Business of GlaxoSmithKline 73
Novartis Pharma Acquires Immunotherapy Manufacturing Facility From Dendreon For US$43 Million 75
SensoMotoric Sells Ophthalmic Division To Alcon Labs 76
Sandoz Completes Acquisition Of Four Generic Products From Watson Pharma And Actavis 77
Galera Therapeutics Raises USD70 Million in Series C Venture Financing 78
Coda Biotherapeutics Raises USD19 Million in Series A Financing 80
Twentyeight-Seven Therapeutics Raises USD65 Million in Series A Venture Financing 81
Artios Pharma Raises USD83.6 Million in Series B Venture Financing 83
Akouos Raises USD50 Million in Series A Financing 85
Enterprise Therapeutics Raises USD41.1 Million in Series B Venture Financing 87
Oculis Raises USD20.51 Million in Series B Financing 89
Expansion Therapeutics Raises USD55.3 Million in Series A Financing 91
Semma Therapeutics Raises USD114 Million in Series B Financing 93
Perlara Raises USD7.4 Million in Venture Financing 95
Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 96
ImaginAb Raises USD7.7 Million in Venture Financing 98
Rani Therapeutics Raises USD39 Million in Series D Financing 99
Homology Medicines Raises USD83.5 Million in Series B Financing 101
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 103
NeuroVia Raises USD14 Million in Series A Financing 105
E-scape Bio Raises Additional USD8 Million in Series A Financing 106
Anaeropharma Science Raises USD13.2 Million in Venture Financing 108
Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 109
ONL Therapeutics Raises USD4.2 Million in Series A Venture Financing 111
Vivet Therapeutics Raises USD41 Million in Series A Venture Financing 112
Cavion Raises USD26 Million in Series A Financing 114
Inflazome Raises USD17 Million in Series A Financing 115
Rox Medical Raises USD40 Million in Series E Financing 116
Annexon Biosciences Raises USD44 Million in Series B Financing 117
IFM Therapeutics Raises USD27 Million in Series A Financing Round 118
F2G Raises USD60 Million in Venture Financing 119
Blade Therapeutics Raises USD27 Million in Series B Financing 121
Caribou Biosciences Raises USD30 Million in Series B Financing Round 123
Ideaya Biosciences Raises USD46 Million in Series A Financing 125
Rani Therapeutics Raises Funds in Financing 127
Galera Therapeutics Raises Additional USD5 Million in Series B Financing 129
Adicet Bio Raises USD51 Million in Series A Financing Round 130
C4 Therapeutics Raises USD73 Million in Series A Financing Round 131
Effector Therapeutics Raises USD40 Million in Series B Venture Financing 132
Galera Therapeutics Raises USD37 Million in Series B Financing 134
Proteostasis Therapeutics Raises USD37 Million in Series B Financing 135
Intellia Therapeutics Raises USD70 Million in Series B Financing 137
Merus Raises USD46.4 Million in First Tranche of Series C Financing 139
Encore Vision Raises USD2.5 Million in Series C Financing 141
E-scape Bio Raises USD55 Million in Series A Financing 142
Ra Pharma Raises USD58.5 Million in Series B Financing 144
Advanced Accelerator Applications Raises USD26 Million in Venture Financing 146
Kanyos Bio Raises USD16 Million in Venture Financing 147
Arcus Biosciences Raises USD50 Million in Series A Financing 148
Rani Therapeutics Raises USD25 Million in Series C Venture Financing 150
Innocrin Pharma Raises USD28 Million in Series D Financing 151
Nabriva Therapeutics Raises USD120 Million in Series B Financing 152
Caribou Biosciences Raises USD11 Million in Series A Financing 154
Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 156
Neurovance Raises Additional USD5.5 Million in Venture Financing 157
Macrolide Pharma Raises USD22 Million in Series A Financing 158
Merganser Biotech Raises USD28 Million in Series A Financing 159
Vaxin Raises USD16 Million in Venture Financing 160
Surface Oncology Raises USD35 Million in Series A Financing 161
Annexon Bioscience Raises USD34 Million in Series A-1 Venture Financing 163
Intellia Therapeutics Raises USD15 Million in Series A Venture Financing 164
Ziarco Raises USD33 Million in Series B Venture Financing 165
Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 166
Quartet Medicine Raises USD17 Million in Series A Venture Financing 168
Innocrin Pharma Raises Funds through Venture Financing 169
Forendo Pharma Raises USD15.3 Million in Series A Venture Financing 170
Viamet Pharma Raises USD60 Million in Series D Venture Financing 172
Raze Therapeutics Raises USD24 Million in Series A Venture Financing 173
Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 175
Encore Vision Raises USD1.7 Million in Venture Financing 176
Neurovance Raises Additional USD4 Million in Venture Financing 177
Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 178
Sorbent Therapeutics Raises USD6.5 Million In First Tranche Of Series D Financing 179
ImaginAb Raises USD21 Million in Series B Venture Financing 180
Anokion Raises US$37.5 Million In Series A Venture financing 181
Aerpio Therapeutics Raises Us$22 Million In Venture Financing 182
Spinifex Pharma Raises USD6.2 Million in Venture Financing 184
Spinifex Pharma Raises US$45 Million In Series C Financing 185
Alios BioPharma Raises US$41 Million In Series B Venture Financing 187
Thesan Pharma Raises US$49 Million In Series B Venture Financing 188
Covagen Raises US$50.3 Million In Series B Financing 189
Advanced Accelerator Applications Raises US$56 Million In Venture Financing 191
Encore Vision Secures USD5 Million in Venture Funding 192
Aileron Therapeutics Raises US$30 Million In Series E Financing 193
Aerpio Therapeutics Raises US$9 Million In Extended Series A Financing 195
Merus Raises US$42 Million In Extended Series B Financing 197
Opsona Therapeutics Raises USD46.8 Million In Extended Series C Financing 199
Akebia Therapeutics Raises US$41 Million In Series C Financing 201
Advanced Accelerator Raises US$6 Million In First Tranche Of Venture Financing 202
Effector Therapeutics Raises US$45 Million In Series A Financing 203
Tokai Pharma Raises US$35.5 Million In Series E Financing 205
Neurovance Raises US$6 Million In Series A1 Financing 206
GenSight Biologics Raises US$41.6 Million In Series A Financing 208
Catalyst Biosciences Secures USD5.07 Million in Venture Funding 210
CoStim Pharma Raises US$10 Million In Venture Financing 212
Aileron Raises US$12 Million In Extended Series D Financing 213
Bicycle Therapeutics Raises US$6 Million In Venture Financing 215
Galera Therapeutics Raises US$11 Million In Series A Financing 217
Ziarco Pharma Raises US$6 Million In First Tranche Of Series A financing 218
Thesan Pharma Raises Additional US$12 Million In Series A Financing 219
Qurient Raises US$4 Million In Venture Financing 220
Selexys Pharma Raises US$23 Million In Series A Financing 221
F2G Raises US$30 Million In Venture Financing 222
Aerpio Therapeutics Raises US$27 Million In Series A Financing 223
PharmAbcine Raises US$3.5 Million In Series B Financing 224
Ra Pharma Raises US$8.6 Million In Second Tranche Of Series A Financing 225
Celladon Raises Additional US$10 Million In Series D Financing 226
BioRelix Raises US$0.27 Million In Venture Financing 228
Advanced Animal Diagnostics Secures USD4 Million in Second Tranche of Series B Funding 229
Akebia Therapeutics Secures Additional US$4.1 Million In Series B Financing 230
AMP Therapeutics Raises Funds Through Series A Financing 231
Samara Capital Partners Acquires Anti-Infective Brands from Novartis 232
Gamida Cell Raises USD40 Million in Private Financing 233
Ampersand Capital Partners and 1315 Capital Acquires Genoptix 235
dievini Hopp BioTech Acquires Remaining Stake in LTS Lohmann Therapie-Systeme from Novartis and BWK 236
Klox Technologies Enters Into Licensing Agreement With Sandoz Canada 237
Pfizer Enters into Co-Development Agreement with Novartis 238
Global Antibiotic Research & Development Partnership Enters into Partnership with Novartis 239
Novartis and Mundipharma Enter into Agreement 240
Novartis and Albumedix Enter into Agreement 241
Pear Therapeutics Enters into Agreement with Sandoz 242
Novartis to Enter into Agreement with Wyss Institute for Biologically Inspired Engineering at Harvard 243
Pear Therapeutics Enters into Agreement with Novartis 244
Novartis and Bill & Melinda Gates Foundation Enter into Partnership 245
Sandoz International Enters into Agreement with Biocon 246
Homology Medicines Enters into Agreement with Novartis 247
Novartis Enters into Agreement with University of California 248
Helsinn Therapeutics Enters into Co-Promotion Agreement with Novartis 249
Cipla and Novartis May Enter into Co-Marketing Agreement 250
Oxford BioMedica Enters into Agreement with Novartis 251
Bristol-Myers Squibb Enters into Partnership with Novartis 252
Allergan Enters into Agreement with Novartis 253
Perthera Enters into Agreement with Novartis 254
TARGET PharmaSolutions Enters into Agreement with Novartis 255
Novartis Enters into Option Agreement with Ionis Pharma and Akcea Therapeutics 256
Protagen Enters into Agreement with Novartis Pharma 258
Conatus Pharma Enters into Co-Development Agreement with Novartis Pharma 259
Rovi Enters into Co-Marketing Agreement with Novartis for Neparvis 260
Cerulean Pharma Enters into Partnership with Novartis 261
Perlara Enters into Partnership with Novartis 262
Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 263
Cure Forward Partners with Novartis Pharma 264
Novartis Expands its Agreement with Medicines for Malaria Venture 265
Novartis Pharma Enters into Agreement with Eisai 266
Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 267
Cigna Enters into Contract with Novartis 268
MedinCell Enters into Agreement with Sandoz International 269
Radius Health Partners with Novartis Pharma for RAD1901 270
NeoBiocon Enters into Agreement with Novartis 271
Accelis Pharma Enters into Distribution Agreement with Fougera Pharma 272
Amgen Expands its Co-Development Agreement with Novartis 273
Medicines Company Enters into Distribution Agreement with Sandoz for Angiomax 274
Sosei Plans to Enter into Agreement with Novartis 275
Rani Therapeutics Enters into Agreement with Novartis 276
PaxVax Enters into Distribution Agreement with Novartis 277
Aduro Biotech Enters into Agreement with Novartis for Immuno-Oncology Products 278
Semma Therapeutics Enters into Agreement with Novartis 279
Novartis Enters into Co-Development Agreement with Department of Science & Technology 280
PeptiDream Expands Drug Discovery Agreement with Novartis 281
BioLineRx Enters into Agreement with Novartis Pharma 282
Rega Institute for Medical Research, Centre for Drug Design and Discovery, KRICT Enters into Partnership with Novartis 283
Fougera Pharma Enters into Co-Promotion Agreement with Women’s Choice Pharma for Veregen 284
Covance Enters into Co-Development Agreement with Novartis Institutes for BioMedical Research 285
Novartis Enters into Co-Marketing Agreement with Pharmathen Pharma 286
Novartis Enters into Agreement with Pfizer to Commercialize Ultibro Breezhaler and Seebri Breezhaler 287
Anacor Pharma Amends Co-Marketing Agreement with Sandoz for Kerydin 288
Amgen and Novartis Expands Partnership with Banner Alzheimer Institute 290
Hanmi Pharma Enters into Co-Marketing Agreement with Novartis Korea 291
Servier Expands Agreement with Novartis 292
Cytovance Biologics Enters Into Co-Development Agreement With Selexys Pharma 293
Rovi Enters Into Agreement With Novartis Farma To Market Hirobriz Breezhaler And Ulunar Breezhaler 294
Vect-Horus Enters into Collaboration Agreement with Advanced Accelerator Applications for Radio-Imaging Agents 295
GigaGen Enters into Research Agreement with Novartis 296
Novartis Enters Into Distribution Agreement With WhanIn For Clozaril 297
Oxford BioMedica Enters into Agreement with Novartis 298
Handok Pharma Enters Into Co-Marketing Agreement With Novartis Korea For Onbrez Breezhaler 299
Novartis Institutes for BioMedical Research Enters into Co-Development Agreement with University of Cape Town 300
PeptiDream Expands Macrocylic Peptide Drug Discovery Agreement with Novartis 301
Sandoz Enters Into Co-promotion Agreement With Nipro Pharma For Somatropin BS S.C. Injection 5mg/10mg [Sandoz] 302
AnaptysBio Enters Into Co-Development Agreement With Novartis 303
Ideaya Biosciences Enters into Licensing Agreement with Novartis 304
Boston Pharma Enters into Licensing Agreement with Novartis 305
Novartis Enters into Licensing Agreement with Cellular Biomedicine 306
Novartis Pharma Enters into Licensing Agreement with Galapagos and MorphoSys 308
Lifemax Laboratories Enters into Licensing Agreement with Novartis Pharma 310
Laekna Enters into Licensing Agreement with Novartis Pharma 311
Adlai Nortye Biopharma Enters into Licensing Agreement with Novartis Pharma 312
Everest Medicines Enters into Licensing Agreement with Novartis 313
Novartis Pharma Enters into Licensing Agreement with Bio-Images Drug Delivery 314
Oncology Venture Exercises Option to In-License Dovitinib with Novartis Pharma 315
Novartis Enters into Licensing Agreement with SEAS, Wyss Institute for Biologically Inspired Engineering, Dana-Farber Cancer Institute and University of Michigan 316
Advanced Accelerator Enters into Licensing Agreement with Cancer Targeted Technology 317
BridgeBio Pharma Enters into Licensing Agreement with Novartis 318
Novartis Enters into Licensing and Supply Agreement with Spark Therapeutics 319
Intec Pharma Enters into Agreement with Novartis Pharma 320
Novartis Enters into Licensing Agreement with XOMA for Gevokizumab 321
Laekna Therapeutics Enters into Licensing Agreement Novartis Pharma 322
Sandoz Enters into Licensing Agreement with Vectura 323
Sandoz Amends Licensing Agreement with DURECT 324
Midatech Pharma Enters Into Licensing Agreement with Novartis 325
Novartis Pharma Exercises Option for Licensing Agreement with Conatus Pharma 326
Magenta Therapeutics Enters into Licensing Agreement with Novartis for MGTA-456 327
Novartis Enters into Licensing Agreement with Celyad 328
Novartis Pharma Enters into Licensing Agreement with bluebird bio 329
Novartis Enters into Licensing Agreement with Parvus Therapeutics 330
Novartis Exercises Option for Licensing Agreement with Tribos 331
PureTech Amends Licensing Agreement with Novartis 332
Sandoz International Enters into Licensing Agreement with DSM Sinochem Pharma 333
Novartis Enters into Licensing Agreement with Ligand Pharma 334
Sunovion Pharma Enters into Licensing Agreement with Novartis 335
Sandoz and Beximco Pharma Enter into Licensing Agreement with Medicines Patent Pool 336
Boryung Pharma Enters into Licensing Agreement with Sandoz 337
Novartis Enters into Licensing Agreement with Xencor 338
Advanced Accelerator Applications Enters into Licensing Agreement with Erasmus University Medical Center and Demokritos National Center 339
Kyowa Hakko Kirin Enters into Licensing Agreement with Sandoz 340
Surface Oncology Enters into Licensing Agreement with Novartis 341
Advanced Accelerator Applications Enters into Licensing Agreement with Johns Hopkins University 342
Novartis Enters into Licensing Agreement with Rhizen Pharma 343
Novartis Enters into Licensing Agreement with Palobiofarma 344
Cadent Therapeutics (Luc Therapeutics) Enters into Licensing Agreement with Novartis 345
Novartis Enters into Licensing Agreement with XOMA 346
Novartis to Terminate Licensing Agreement with Aveo Pharma 347
Cytos Biotechnology Enters into License Agreement with Novartis 348
Fujifilm RI Pharma Enters into Licensing Agreement with Advanced Accelerator Applications 349
BioQuiddity Expands Licensing Agreement with Sandoz 350
Apricus Expands Licensing Agreement with Hexal for Vitaros 351
Caribou Biosciences Enters into Licensing Agreement with Novartis 352
Novartis Pharma Enters into Licensing Agreement with Vanda Pharma for AQW-051 353
Novartis Enters into Research and Licensing Agreement with Intellia Therapeutics 354
Oxford BioMedica Enters into Licensing Agreement with Novartis for LentiVector 355
Novartis Enters into Licensing Agreement with Global Alliance for TB Drug Development for Tuberculosis Drugs 356
Ophthotech Amends Licensing Agreement with Novartis 357
Eureka Therapeutics And Memorial Sloan-Kettering Cancer Center Enter Into Licensing Agreement With Novartis 359
Taiwan Liposome Enters Into Licensing Agreement With Sandoz For AmBiL 360
Retrophin Enters Into Licensing Agreement With Novartis Pharma For Syntocinon Nasal Spray 361
Ensemble Therapeutics Enters Into Licensing Agreement With Novartis To Develop Interleukin-17 Antagonists 362
Novartis Enters Into Licensing Agreement With Biological E 363
GenSight Biologics Enters into Licensing Agreement with Novartis Pharma 364
Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 365
Novartis Enters into Licensing Agreement with Boston Scientific for Everolimus 367
Ziarco Pharma Enters Into Licensing Agreement With Pfizer 369
CoStim Pharma Enters into Licensing Agreement with Immutep 370
Novartis Enters Into Licensing Agreement With University of Pennsylvania For All CARs 371
Marina Biotech Enters Into Licensing Agreement With Novartis For CRN Technology 372
Cyon Therapeutics Enters into Licensing Agreement with Novartis 373
PeptiDream Exercises Option for Licensing Agreement with Novartis 374
ProBioGen Enters into Lincencing Agreement with Novartis for GlymaxX ADCC Technology 375
Nuevolution Enters Into Licensing Agreement With Novartis 376
Apricus Biosciences Expands Licensing Agreement With Hexal For Vitaros 377
Novartis Enters Into Licensing Agreement With Regenerex For Facilitating Cell Therapy Platform 378
Life Technologies Enters Into Licensing Agreement With Novartis 379
Themis Medicare Enters Into Licensing Agreement With Novartis India For Diclofenac Topical Gel 380
Taisho Pharma Enters Into Licensing Agreement With Novartis Pharma For TS-071 381
Zalicus Extends Licensing Agreement With Novartis Institutes For Oncology Combinations 382
Novartis Amends Licensing Agreement With AlphaVax 383
Cellular Biomedicine Plans to Raise up to USD25.5 Million in Public Offering of Shares 384
Surface Oncology Raises USD11.5 Million in Private Placement of Shares 385
ThromboGenics Plans to Raise USD11.8 Million in Private Placement of Shares 386
Altimmune Raises USD14.7 Million in Private Placement of Series B Preferred Shares 387
Akcea Therapeutics Raises USD50 Million in Private Placement of Shares 389
Aerpio Pharma Raises USD40 Million in Private Placement of Shares 390
Opsona Therapeutics Raises USD10.58 Million in Private Placement of Shares 391
Perlara Raises Funds in Equity Financing 392
Advanced Accelerator Applications Prices Public Offering of American Depositary Shares for USD172.5 Million 393
Advanced Accelerator Applications to Raise up to USD80 Million in IPO 395
Intellia Therapeutics Raises USD70 Million in Private Placement of Series B Preferred Stock 397
Anokion to Raise USD16 Million in Private Placement of Shares 399
Aduro BioTech Raises USD25 Million in Private Placement Shares 400
Tokai Pharma Raises USD0.71 Million in Public Offering of Shares 401
Caribou Biosciences Raises Funds through Private Placement of Shares 402
Vanda Pharma Raises USD25 Million in Private Placement of Common Stock 403
Intercell Completes Private Placement Of Shares For US$19.8 Million 405
Novartis Raises USD925 Million in Public Offering of 0.5% Bonds Due 2023 406
Novartis Raises USD925 Million in Public Offering of 1.375% Notes Due 2030 407
Novartis Raises USD925 Million in Public Offering of 1.7% Notes Due 2038 408
Novartis Raises USD647.19 Million in Public Offering of International Bonds Due 2027 409
Novartis Raises USD1.3 Billion in Public Offering of International Bonds Due 2021 410
Novartis Raises USD561.78 Million in Public Offering of International Bonds Due 2028 411
Novartis Raises USD1.40 Billion in Public Offering of International Bonds Due 2023 412
Novartis Raises USD1.75 Billion in Public Offering of 3% Bonds Due 2025 413
Novartis Raises USD1.25 Billion in Public Offering of 4% Bonds Due 2045 414
Novartis Prices Public Offering of 0.75% Notes Due 2021 for USD756.5 Million 415
Novartis Prices Public Offering of 1.625% Notes Due 2026 for USD756.5 Million 416
Novartis Raises USD1.85 Billion in Public Offering of 4.4% Bonds Due 2044 417
Novartis Raises USD2.15 Billion in Public Offering of 3.4% Bonds Due 2024 418
Novartis Completes Public Offering Of 2.4% Senior Notes Due 2022 For US$1.5 Billion 419
Novartis Completes Public Offering Of 3.7% Senior Notes Due 2042 For US$500 Million 420
Eyevance Pharma Acquires FLAREX from Novartis 421
Avara Pharmaceutical Services Acquires Sterile Manufacturing Facility and Development Center from Novartis 422
Aurobindo Pharma USA to Acquire Dermatology Generics Business from Sandoz 423
Olon to Acquire API Manufacturing Facility from Novartis 424
Mylan Acquires TOBI Podhaler and TOBI Solution from Novartis for USD463 Million 425
Clinigen Acquires Proleukin from Novartis 426
NTC Acquires Ocular Antibiotic Products from Novartis 427
Novartis May Sell US Generic Pill Business 428
CASI Pharma Acquires ANDA Portfolio from Sandoz 430
Shanghai Fosun Pharma Plans to Acquire Medicine Products from Sandoz for USD18 Million 431
Torrent Pharma Acquires Two Brands of Women Healthcare Segment from Novartis 432
Lotus Pharma Acquires Osteoporosis from Novartis 433
Sun Pharma to Acquire Odomzo from Novartis 434
Novartis May Sell Ritalin, Clozaril and Exelon Drugs 435
Upsher-Smith Labs Acquires 20 US Generic Products from Sandoz 436
Noden Pharma Acquires Rights to Tekturna and Tekturna HCT from Novartis 437
China NT Pharma to Acquire Miacalcic Injectable and Miacalcic Spray from Novartis for USD145 Million 438
Sun Pharma Acquires 14 Brands from Novartis for USD293 Million 439
CSL Acquires Influenza Vaccines Business of Novartis for USD275 Million 440
Mereo BioPharma Acquires Clinical Assets from Novartis 444
Merus Labs Acquires Rights to Salagen and Estraderm MX from Novartis Pharma for USD30 Million 445
Arrowhead Research Acquires RNAi R&D Portfolio from Novartis for USD35 Million 446
GlaxoSmithKline Acquires Consumer Healthcare Pharma Business of Novartis 447
Array BioPharma Acquires Encorafenib from Novartis Pharma 449
GlaxoSmithKline Acquires Vaccines Business of Novartis for up to USD7.1 Billion 451
Aspen Pharmacare Acquires Rights to Mono-Embolex from Novartis 453
China Medical System Acquires Rights to Lamisil and Parlodel from Novartis 454
Tribute Pharma Acquires Canadian Rights to Fiorinal, Fiorinal C, Visken and Viskazide from Novartis 456
Merus Labs Acquires Sintrom from Novartis 457
Novartis India to Sell Its OTC Division to GlaxoSmithKline Consumer 458
Lansen Pharma Acquires Sicorten Plus From Novartis For USD9.5 Million 459
Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 460
Alliance Pharma Acquires Rights To Lypsyl From Novartis For US$3 Million 462
Questcor Pharma Acquires Rights To Synacthen And Synacthen Depot 463
Alliance Pharma Acquires Overseas Rights To Syntometrine From Novartis For US$11.5 Million 465
Clinigen Acquires Cardioxane, Oncology Support Therapy, From Novartis For US$33 Million 466
Validus Pharma And Wood Creek Capital Management Acquire Six Product Lines From Novartis Pharma 467
Merus Labs Completes Acquisition Of Prescription Medicine Product From Novartis 469
Novartis to Acquire Endocyte 470
GlaxoSmithKline Acquires Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD13 Billion 472
Novartis Acquires AveXis for USD8.7 Billion 474
Novartis Acquires Advanced Accelerator Applications for USD3.9 Billion 476
Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 478
Novartis May Acquire Genfit 480
Novartis Acquires Encore Vision 481
Novartis Acquires Ziarco Group 482
Novartis Pharma Acquires Selexys Pharma for up to USD665 Million 483
Novartis May Acquire Amneal Pharma 485
International Chemical Investors Acquires Sandoz Industrial Products from Novartis 486
Advanced Accelerator Applications Acquires IDB Group 487
Novartis Acquires Admune Therapeutics 488
Novartis to Acquire Additional 2.5% Stake in Gamida Cell for USD15 Million 489
Novartis Acquires Spinifex Pharma 490
Advanced Accelerator Applications Acquires Remaining 49.9% Stake in Atreus Pharma 491
Novartis Pharma Acquires 15% Stake in Gamida Cell for USD35 Million 492
Novartis Acquires CoStim Pharma 493
Novartis To Acquire Sideris Pharma For Up To US$300 Million 495
GlaxoSmithKline Acquires Okairos For US$325 Million 496
Pfizer, Novartis And Abbott Labs Reportedly Plan To Bid For Ache Labs 498
Takeda America Completes Acquisition Of LigoCyte Pharma For US$60 Million 500
Novartis Completes Acquisition Of Fougera Pharma, Dermatology Company, For US$1.5 Billion 502
Takeda Completes Acquisition Of Intellikine For US$310 Million 504
Novartis AG, Key Competitors 506
Novartis AG, Key Employees 507
Novartis AG, Subsidiaries 509
List of Figures
Novartis AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Novartis AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Novartis AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20
Novartis AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 21
Novartis AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22
Novartis AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23
Novartis AG, Medical Devices Deals, 2012 to YTD 2018 25
Novartis AG (NOVN)：製薬・医療：M&Aディール及び事業提携情報 |
◆英語タイトル：Novartis AG (NOVN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9858
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：669
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：スイス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
【レポートの概要】
◆商品コード：DATA904C9858
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：669
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：スイス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
| Single User（1名様閲覧用） | USD250 ⇒換算￥37,000 | 見積依頼/購入/質問フォーム |
| Site License（同一事業所内共有可） | USD500 ⇒換算￥74,000 | 見積依頼/購入/質問フォーム |
| Enterprisewide License（複数事業所内共有可） | USD750 ⇒換算￥111,000 | 見積依頼/購入/質問フォーム |
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers eye care products through its subsidiary, Alcon; and generic medicines and biosimilars through Sandoz. Novartis carries out research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices in the Americas, Europe, the Middle East, Africa and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
Novartis AG (NOVN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
【レポートの目次】
| ★海外企業調査レポート[Novartis AG (NOVN)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら |
